Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.

BACKGROUND

Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful.

CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size.

CONCLUSION

Tolvaptan may be a useful treatment for severe neonatal PKD.